Releases Details

Gaithersburg, Maryland – September 14, 2017: MaxCyte, a US-based global company driving the acceleration of the discovery, development, manufacturing and commercialization of next-generation, cell-based medicines, announced today that Madhusudan V. Peshwa, PhD, MaxCyte Chief Scientific Officer, Executive Vice President, Cellular Therapies, will present at the Phacilitate Cell & Gene Therapy Europe conference to be held September 19-21, 2017 in Berlin, Germany.

Dr. Peshwa will moderate and present an overview of MaxCyte’s clinically and commercially validated, regulatory compliant, automated, cGMP closed system platform technology for ex vivo non-viral delivery, in a panel discussion on September 21 at 11:35 a.m. CEST entitled, “Assessing the latest non-viral delivery technologies – Can we define their real potential to deliver improvements on viral alternatives and/or to open up new indications and markets to gene therapy?” Also as part of this panel, he will deliver a case study presentation at 3 p.m. CEST that day, within the track: R&D Updates & Emerging Science: Gene Editing Platforms. The case study will describe pre-clinical in vitro and animal model results, as well as translational development of scalable cGMP compliant processes for manufacture of gene-corrected hematopoietic stem cells, as potential treatment for genetic diseases.

“Our focus at MaxCyte is to support our biopharmaceutical partners in bringing to market next-generation cell-based medicines, and we’re pleased to contribute to industry discussions on how to successfully commercialize those products using our MaxCyte GT® Flow Electroporation™ System,” said Doug Doerfler, MaxCyte President & CEO MaxCyte.

More information on the conference is available at: www.cgteurope.com/

About MaxCyte
MaxCyte is a US-based global company driving the acceleration of the discovery, development, manufacturing and commercialization of next-generation, cell-based medicines. The Company provides its patented, high-performance cell engineering platform to biopharmaceutical partners engaged in drug discovery and development, biomanufacturing, and cell therapy, including gene editing and immuno-oncology. With its robust delivery platform, MaxCyte’s team of scientific experts helps its partners to unlock their product potential and solve problems. This platform allows for the engineering of nearly all cell types, including human primary cells, with any molecule, at any scale. It also provides a high degree of consistency and minimal cell disturbance, thereby facilitating rapid, large-scale, clinical and commercial grade cell engineering in a non-viral system and with low-toxicity concerns. The Company’s cell-engineering platform is FDA-accredited, providing MaxCyte’s customers and partners with an established regulatory path to commercialize cell-based medicines. MaxCyte is also developing CARMA, its proprietary, breakthrough platform in immuno-oncology, to rapidly manufacture CAR therapies for a broad range of cancer indications, including solid tumors where existing CAR-T approaches face significant challenges. For more information, visit /

###